Health Trials

About this trial

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Eligibility criteria

Qualifiers

Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

Able to take oral medication

If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements

Adequate organ function and electrolytes

Disqualifiers

Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812

Impaired cardiac function

Major surgery within 28 days of the first dose of study drug

Trial design

Treatments tested in this trial

  • DCC-2812

Treatment groups

60 Participants
are divided into 1 treatment group

Locations

5
Dana-Farber Cancer Institute02215, BostonMassachusetts, United States
University of Michigan48109, Ann ArborMichigan, United States
Vanderbilt- Ingram Cancer Center37232, NashvilleTennessee, United States
NEXT Oncology, Austin78758, AustinTexas, United States

Sponsors and collaborators

Deciphera Pharmaceuticals, LLC

Lead sponsor

Source ClinicalTrials.gov